High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
about
MicroRNAs as growth regulators, their function and biomarker status in colorectal cancerMicroRNAs: Clinical Relevance in Colorectal CancerAn update on microRNAs as colorectal cancer biomarkers: where are we and what's next?FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancermiR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cellsColorectal Cancer: From the Genetic Model to Posttranscriptional Regulation by Noncoding RNAs.The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer.MiR-625-3p promotes cell migration and invasion via inhibition of SCAI in colorectal carcinoma cells.Use of microRNAs in directing therapy and evaluating treatment response in colorectal cancer.Evaluation of plasma microRNA levels to predict insensitivity of patients with advanced lung adenocarcinomas to pemetrexed and platinum.MicroRNA-93-5p increases multidrug resistance in human colorectal carcinoma cells by downregulating cyclin dependent kinase inhibitor 1A gene expression.MicroRNAs in colorectal cancer as markers and targets: Recent advances.Involvement of Non-coding RNAs in Chemo- and Radioresistance of Colorectal Cancer.Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance.The role of exosomes and miRNAs in drug-resistance of cancer cells.MicroRNAs as a tool to aid stratification of colorectal cancer patients and to guide therapy.miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation.Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment.Down-regulation of miRNA-148a and miRNA-625-3p in colorectal cancer is associated with tumor budding.Peroxisome Proliferator-Activated Receptor Gamma in Obesity and Colorectal Cancer: the Role of EpigeneticsSerum microRNA-135a-5p as an auxiliary diagnostic biomarker for colorectal cancer.Putting a brake on stress signaling: miR-625-3p as a biomarker for choice of therapy in colorectal cancer.MicroRNAs as Biomarkers in Colorectal Cancer.Prognostic value of microRNAs in colorectal cancer: a meta-analysis.miRNAs and lncRNAs as Predictive Biomarkers of Response to FOLFOX Therapy in Colorectal CancerCombination of a six microRNA expression profile with four clinicopathological factors for response prediction of systemic treatment in patients with advanced colorectal cancer
P2860
Q26775610-812A737D-13F9-448A-8A7D-1EAC1AACCDBFQ26776039-573C56F6-EF32-4301-AC82-AE86CD71D675Q27024427-D902D6AB-8497-460D-9B1F-E4B31CF33206Q28075540-CD34E9F0-803D-4559-8559-9D63FB3594B2Q28829677-98AAFBE6-876A-4F23-A05F-1BFE1EA45651Q33720978-CF5627E3-727A-433A-A416-EB3CFB98ADCFQ35638525-66447C73-814C-4120-9EE9-F9EF9ED3B25CQ36413914-9A8F7B51-7E0F-4B25-811E-75ED31A5B4FEQ36963164-091DAC47-EEC4-4786-8667-2C5E2FAA5593Q37581936-02963BC4-6849-4A67-B843-FE169A747666Q37700939-615825A6-15C1-4B99-A228-445417FD81BEQ37708024-A8188CC5-B63E-44C7-B1B8-96A73DAA62FBQ38826542-D759EA3F-FBE2-40F9-94F2-FA4D7EA1F8DEQ38901400-C0ED402B-E008-433C-A450-613C34F57061Q39152624-59DA9390-8132-4AEF-B5EB-8691A2A4FB12Q39390383-FD5ABC88-FBD3-4F06-A802-133D648DF37CQ40064947-540754F7-A251-4A78-8B8D-7588659D9D7EQ41134824-8C9FC6FC-B0E4-4A7B-BD06-EFA291CBB5CFQ41589141-9FD9BC5A-2937-4016-84AC-AEF2770660E1Q41631623-A8215DEF-118F-4C16-94CB-25352D6ABFD8Q53112003-2C75FF8A-ED17-4A06-9BE9-A16784525353Q53762655-54812E49-65DA-4247-BA6B-419BAC04B072Q55042978-8AFD07F8-A662-416B-885D-E26A2A57A64AQ55307845-87EA585A-2980-4B7A-B8EA-37FDE41E51F6Q58799032-89A410D6-4EE8-4F92-AE3A-331C53CC69FBQ58802479-9348DC0E-E579-4FE4-84E6-A8B77A58CC40
P2860
High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer.
description
2013 nî lūn-bûn
@nan
2013 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
High expression of microRNA-62 ...... metastatic colorectal cancer.
@ast
High expression of microRNA-62 ...... metastatic colorectal cancer.
@en
High expression of microRNA-62 ...... metastatic colorectal cancer.
@nl
type
label
High expression of microRNA-62 ...... metastatic colorectal cancer.
@ast
High expression of microRNA-62 ...... metastatic colorectal cancer.
@en
High expression of microRNA-62 ...... metastatic colorectal cancer.
@nl
prefLabel
High expression of microRNA-62 ...... metastatic colorectal cancer.
@ast
High expression of microRNA-62 ...... metastatic colorectal cancer.
@en
High expression of microRNA-62 ...... metastatic colorectal cancer.
@nl
P2093
P2860
P50
P1433
P1476
High expression of microRNA-62 ...... f metastatic colorectal cancer
@en
P2093
Benny V Jensen
Flemming Hansen
Jan Lindebjerg
Lise L Christensen
Mads H Rasmussen
Maria U Rømer
Niels F Jensen
Nils Brünner
Tine P Hansen
Torben F Hansen
P2860
P304
P356
10.1016/J.MOLONC.2013.02.016
P577
2013-02-28T00:00:00Z